These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 18284634)

  • 1. RET genotypes in sporadic medullary thyroid cancer: studies in a large Italian series.
    Fugazzola L; Muzza M; Mian C; Cordella D; Barollo S; Alberti L; Cirello V; Dazzi D; Girelli ME; Opocher G; Beck-Peccoz P; Persani L
    Clin Endocrinol (Oxf); 2008 Sep; 69(3):418-25. PubMed ID: 18284634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of RET polymorphisms and haplotypes in the context of sporadic medullary thyroid carcinoma.
    Fernández RM; Peciña A; Antiñolo G; Navarro E; Borrego S
    Thyroid; 2006 Apr; 16(4):411-7. PubMed ID: 16646689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association study of 69 genes in the ret pathway identifies low-penetrance loci in sporadic medullary thyroid carcinoma.
    Ruiz-Llorente S; Montero-Conde C; Milne RL; Moya CM; Cebrián A; Letón R; Cascón A; Mercadillo F; Landa I; Borrego S; Pérez de Nanclares G; Alvarez-Escolá C; Díaz-Pérez JA; Carracedo A; Urioste M; González-Neira A; Benítez J; Santisteban P; Dopazo J; Ponder BA; Robledo M;
    Cancer Res; 2007 Oct; 67(19):9561-7. PubMed ID: 17909067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does the RET variant G691S influence the features of sporadic medullary thyroid carcinoma?
    Cardot-Bauters C; Leteurtre E; Leclerc L; Vantyghem MC; Do Cao C; Wemeau JL; d'Herbomez M; Carnaille B; Barbu V; Pinson S; Pigny P;
    Clin Endocrinol (Oxf); 2008 Sep; 69(3):506-10. PubMed ID: 18331611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical relevance of RET variants G691S, L769L, S836S and S904S to sporadic medullary thyroid cancer.
    Machens A; Frank-Raue K; Lorenz K; Rondot S; Raue F; Dralle H
    Clin Endocrinol (Oxf); 2012 May; 76(5):691-7. PubMed ID: 22111543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional characterization of the MTC-associated germline RET-K666E mutation: evidence of oncogenic potential enhanced by the G691S polymorphism.
    Borrello MG; Aiello A; Peissel B; Rizzetti MG; Mondellini P; Degl'Innocenti D; Catalano V; Gobbo M; Collini P; Bongarzone I; Pierotti MA; Greco A; Seregni E
    Endocr Relat Cancer; 2011 Aug; 18(4):519-27. PubMed ID: 21690267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [RET and GFRA1 germline polymorphisms in medullary thyroid cancer patients].
    Severskaia NV; Saenko VA; Il'in AA; Chebotareva IV; Rumiantsev PO; Isaev PA; Medvedev VS; Iasmita S
    Mol Biol (Mosk); 2006; 40(3):425-35. PubMed ID: 16813162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The RET polymorphic allele S836S is associated with early metastatic disease in patients with hereditary or sporadic medullary thyroid carcinoma.
    Siqueira DR; Romitti M; da Rocha AP; Ceolin L; Meotti C; Estivalet A; Puñales MK; Maia AL
    Endocr Relat Cancer; 2010 Dec; 17(4):953-63. PubMed ID: 20801952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymorphisms in the initiators of RET (rearranged during transfection) signaling pathway and susceptibility to sporadic medullary thyroid carcinoma.
    Cebrian A; Lesueur F; Martin S; Leyland J; Ahmed S; Luccarini C; Smith PL; Luben R; Whittaker J; Pharoah PD; Dunning AM; Ponder BA
    J Clin Endocrinol Metab; 2005 Nov; 90(11):6268-74. PubMed ID: 16091499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymorphisms Within the
    Gemignani F; Romei C; Ciampi R; Corrado A; Melaiu O; Figlioli G; Bonotti A; Foddis R; Cristaudo A; Pellegrini G; Vivaldi A; Cipollini M; Landi S; Elisei R
    Thyroid; 2020 Nov; 30(11):1579-1588. PubMed ID: 32228166
    [No Abstract]   [Full Text] [Related]  

  • 11. Four novel RET germline variants in exons 8 and 11 display an oncogenic potential in vitro.
    Muzza M; Cordella D; Bombled J; Bressac-de Paillerets B; Guizzardi F; Francis Z; Beck-Peccoz P; Schlumberger M; Persani L; Fugazzola L
    Eur J Endocrinol; 2010 Apr; 162(4):771-7. PubMed ID: 20103606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In silico and in vitro analysis of rare germline allelic variants of RET oncogene associated with medullary thyroid cancer.
    Cosci B; Vivaldi A; Romei C; Gemignani F; Landi S; Ciampi R; Tacito A; Molinaro E; Agate L; Bottici V; Cappagli V; Viola D; Piaggi P; Vitti P; Pinchera A; Elisei R
    Endocr Relat Cancer; 2011 Oct; 18(5):603-12. PubMed ID: 21810974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polymorphisms in exon 13 and intron 14 of the RET protooncogene: genetic modifiers of medullary thyroid carcinoma?
    Baumgartner-Parzer SM; Lang R; Wagner L; Heinze G; Niederle B; Kaserer K; Waldhäusl W; Vierhapper H
    J Clin Endocrinol Metab; 2005 Nov; 90(11):6232-6. PubMed ID: 16118333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of RET polymorphisms in a six-generation family with G533C RET mutation: specific RET variants may modulate age at onset and clinical presentation.
    Tamanaha R; Camacho CP; Pereira AC; da Silva AM; Maciel RM; Cerutti JM
    Clin Endocrinol (Oxf); 2009 Jul; 71(1):56-64. PubMed ID: 19138318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The modifier role of RET-G691S polymorphism in hereditary medullary thyroid carcinoma: functional characterization and expression/penetrance studies.
    Colombo C; Minna E; Rizzetti MG; Romeo P; Lecis D; Persani L; Mondellini P; Pierotti MA; Greco A; Fugazzola L; Borrello MG
    Orphanet J Rare Dis; 2015 Mar; 10():25. PubMed ID: 25887804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The influence of gender, age, and RET polymorphisms on C-cell hyperplasia and medullary thyroid carcinoma.
    Weinhaeusel A; Scheuba C; Lauss M; Kriegner A; Kaserer K; Vierlinger K; Haas OA; Niederle B
    Thyroid; 2008 Dec; 18(12):1269-76. PubMed ID: 18976163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RET genetic screening in patients with medullary thyroid cancer: the Moroccan experience.
    Abdelhakim A; Barlier A; Kebbou M; Benabdeljalil N; Timinouni M; Taoufiq F; Roche C; El Antri S
    J Cancer Res Ther; 2009; 5(3):198-202. PubMed ID: 19841562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of germline sequence variants of GFRA1, GFRA2, and GFRA3 genes in a cohort of Spanish patients with sporadic medullary thyroid cancer.
    Borrego S; Fernández RM; Dziema H; Japón MA; Marcos I; Eng C; Antiñolo G
    Thyroid; 2002 Nov; 12(11):1017-22. PubMed ID: 12490080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Germline RET sequence variation I852M and occult medullary thyroid cancer: harmless polymorphism or causative mutation?
    Machens A; Spitschak A; Lorenz K; Pützer BM; Dralle H
    Clin Endocrinol (Oxf); 2011 Dec; 75(6):801-5. PubMed ID: 21711375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the role of RET polymorphisms/haplotypes as modifier loci for MEN 2, and analysis of the correlation with the type of RET mutation in a series of Spanish patients.
    Fernández RM; Navarro E; Antiñolo G; Ruiz-Ferrer M; Borrego S
    Int J Mol Med; 2006 Apr; 17(4):575-81. PubMed ID: 16525712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.